Tin tức & Cập nhật
Xem bài viết Nội tiết
Xem

Concomitant insulin may counter renoprotective effects of SGLT2is in T2D patients with CKD
Renal composite outcomes (RCO) appear to be less favourable among type 2 diabetes (T2D) patients with chronic kidney disease (CKD) treated with insulin and sodium-glucose cotransporter 2 inhibitors (SGLT2i), a recent Japan study has found.
Concomitant insulin may counter renoprotective effects of SGLT2is in T2D patients with CKD
16 Jun 2022
Is SGLT-2 inhibitor better than metformin as first-line T2D treatment?
Use of sodium–glucose cotransporter-2 inhibitors (SGLT-2i) as first-line treatment for type 2 diabetes (T2D) delivers a comparable risk for myocardial infarction (MI), stroke, and mortality; a lower risk for hospitalization for heart failure (HHF)/mortality and HHF; and a similar safety profile, except for a higher risk for genital infections, when compared to treatment with metformin, a study has found.
Is SGLT-2 inhibitor better than metformin as first-line T2D treatment?
15 Jun 2022
‘Digital Twin’ tech reverses type 2 diabetes, fixes metabolic disruptions
A novel artificial intelligence platform that integrates multidimensional data to deliver precision nutrition and health recommendations not only helps to induce remission in type 2 diabetes but also to normalize a range of glycaemic and extraglycaemic parameters, as shown in a study presented at the 82nd American Diabetes Association (ADA) Scientific Sessions.
‘Digital Twin’ tech reverses type 2 diabetes, fixes metabolic disruptions
14 Jun 2022
Higher dairy intake tied to lower T2D risk
Higher consumption of dairy products is associated with a lower risk of type 2 diabetes (T2D) among US adults, according to a nationally representative study presented at ADA 2022.
Higher dairy intake tied to lower T2D risk
14 Jun 2022
CREATE: ‘Open-source’ automated insulin delivery gets good results in T1D
Automating insulin delivery with an open-source algorithm that is run on a smartphone proves safe and effective in the management of type 1 diabetes (T1D), as shown in the results of Community Derived Automated Insulin Delivery (CREATE) trial.
CREATE: ‘Open-source’ automated insulin delivery gets good results in T1D
13 Jun 2022
Weight loss boosts quality of life in type 2 diabetes
Patients with type 2 diabetes (T2D) who lose more weight appear to have better quality of life (QoL), an effect that is independent of treatments received, according to a study presented at the recent 82nd Scientific Sessions by the American Diabetes Association (ADA 2022).
Weight loss boosts quality of life in type 2 diabetes
13 Jun 2022
Central obesity in women with axSpA leads to worse outcomes
Central obesity, as assessed by the waist-to-hip ratio (WHR), is very common in patients with axial spondyloarthritis (axSpA), particularly in women, reveals a recent study. This modifiable comorbidity may result in worse quality of life, worse disease activity, and greater impairment of functional ability.


